Skip to content Skip to footer

Prohibition Partners: Oceania cannabis market could be worth US$1.55b

Prohibition Partners: Oceania cannabis market could be worth US$1.55b
Share this story

The findings come from The Oceania Cannabis Report: Second Edition, the latest addition to the Prohibition Partners’ suite of regional cannabis market reports.

The Oceania Cannabis Report: Second Edition is the most extensive review of the cannabis sector in Australia, New Zealand and surrounding islands. In line with Prohibition Partners’ other market-leading reports, this newest addition includes detailed market value forecasts, examines potential commercial and regulatory developments, and offers in-depth analysis of the countries and companies that are operating at the cutting edge of the Australian, New Zealand and surrounding islands cannabis industries.

Key insights from the report include:

  • The legal cannabis market is expected to be worth US$1.55 billion by 2024 in Australia, New Zealand and the surrounding islands, with medicinal cannabis accounting for approximately 40% of the market.
  • Since the first edition of the Oceania Cannabis Report, two additional territories have legalised adult-use cannabis: the Australian Capital Territory (ACT) and Guam.
  • Australia is expected to account for 79% of the region’s overall market by 2024, due to a comparably larger population and higher household disposable income than New Zealand and the islands across the region.
  • The most transformative legislative change is emanating from the Australia Central Territory, Guam, New Zealand and the Northern Mariana Islands — while Australia is committing to further cannabis science research on a federal level.
  • The next five years are expected to see a falling reliance on imported cannabis products, leading to a sizable increase in domestic revenue generated by the regional cannabis industry.

Prohibition Partners’ Group Managing Director Stephen Murphy said:

“Since our last report on the region, we have seen significant advancement in the Australian and New Zealand cannabis sector. Guam and the Australian Capital Territory have both chosen to legalise recreational cannabis use. Additionally, the New Zealand government announced plans to hold a referendum on recreational cannabis legalisation, which will take place later this year. Australia now boasts over thirty publicly listed cannabis companies on the Australian stock exchange — considerably more than the number currently listed across Europe.”

“In recent months, the region has been faced with great challenges. At the end of 2019 and into 2020, Australia was rocked by devastating wildfires, which claimed in excess of 11 million hectares of land across the country. Australia holds ambitions to become a central player in the global cannabis sector, and the success of this industry could come to play a major role in helping counteract the economic impact of these wildfires.”

“Concerning the global coronavirus (COVID-19) pandemic, it is too early to fully understand the impact that the virus will have on the emerging cannabis industry, especially in Australia. We have seen a double-digit fall in cannabis stock prices on the Australian stock exchange; however, at present there appears to be no significant disruption to the industry’s production and supply lines.”

“How these challenges are affecting and shaping the cannabis industry across the region is explored further in our new report. The Oceania Cannabis Report: Second Edition presents an in-depth analysis on the future potential of the regional cannabis market, its commercial opportunities, regulatory developments, and the major players who are pushing the boundaries of the space.”

About Prohibition Partners

Prohibition Partners unlocks the potential of cannabis through data, intelligence and strategy. We enable our clients to make better business decisions that deliver tangible progress and transformational growth while disrupting mainstream verticals. We work with the industry’s most influential stakeholders, some of the world’s best-known brands and an unrivalled network of analysts, innovators and advisors.

 

Recent posts
June 2, 2022
Austria Sees Record Imports of Medical Cannabis in 2021
May 19, 2022
Who Are Europe’s Medical Cannabis Patients?
May 5, 2022
Europe’s Pilot Trials Are a Tentative Step Towards Legal Medical Cannabis
April 28, 2022
The First Sales of Legal Adult-Use Cannabis in Europe Are Due in 2022

Catch up on our newest articles that you might have missed

joss-woodhead-3wFRlwS91yk-unsplash
June 2, 2022
Austria Sees Record Imports of Medical Cannabis in 2021
Austria sees record imports of medical cannabis in 2021 while a case at the Supreme Court challenges prohibition. Austria is...
Untitled design (11)
May 19, 2022
Who Are Europe’s Medical Cannabis Patients?
The relatively close integration of medical cannabis into the European healthcare systems has contributed to a patient population and purchasing...
il-vagabiondo-Q7QCj-9-q3I-unsplash
May 5, 2022
Europe’s Pilot Trials Are a Tentative Step Towards Legal Medical Cannabis
Underlining the cautious approach Europe is taking to the liberalisation of medical cannabis are the pilot trial access schemes for...
vincent-ghilione-z54zUmYA9f8-unsplash
April 28, 2022
The First Sales of Legal Adult-Use Cannabis in Europe Are Due in 2022
Last week the first pilot project trial for the legalised sales of adult-use cannabis in Basel, Switzerland was approved by...